Research on leiomyosarcomas

From September 2025

Methylation profiling distinguishes two uLMS clusters with unique behaviors, enhancing diagnostic accuracy (ref: Felicelli doi.org/10.1016/j.modpat.2025.100883/)
NTRK fusions in mesenchymal tumors are rare but significant for targeted therapies (ref: Vanacker doi.org/10.1016/j.esmoop.2025.105555/)
Perioperative RT showed no significant impact on cancer-specific mortality in retroperitoneal sarcoma (ref: Baudo doi.org/10.6004/jnccn.2025.7056/)
One-third of sarcoma patients present with synchronous metastases within six months (ref: Heesen doi.org/10.3390/cancers17182944/)
Single-cell RNA sequencing reveals immunosuppressive TME in uterine leiomyosarcoma (ref: Guo doi.org/10.3389/fimmu.2025.1653096/)
Higher dose SBRT improves local control in metastatic sarcoma patients (ref: Hedman doi.org/10.1186/s13014-025-02719-3/)
Subcutaneous leiomyosarcoma classified as high-risk due to significant metastasis potential (ref: Abebe doi.org/10.1002/jso.70095/)
Multimodal treatment strategies are essential for managing sinonasal sarcomas (ref: Vinciguerra doi.org/10.1002/alr.70038/)

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec